4.8 Article

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1423849112

关键词

diabetes; apoCIII; insulin resistance; pancreatic islets

资金

  1. Swedish Diabetes Association
  2. Funds of Karolinska Institutet
  3. Swedish Research Council
  4. Novo Nordisk Foundation
  5. Family Erling-Persson Foundation
  6. Strategic Research Program in Diabetes at Karolinska Institutet
  7. The Family Knut and Alice Wallenberg Foundation
  8. Skandia Insurance Company
  9. Diabetes and Wellness Foundation
  10. The Bert von Kantzow Foundation
  11. Svenska Diabetesstiftelsen
  12. Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant
  13. The Stichting af Jochnick Foundation
  14. Diabetes Research Institute Foundation
  15. Agency for Science, Technology and Research, in Singapore
  16. Human islets were provided through Juvenile Diabetes Research Foundation (JDRF) Award [31-2008-416]
  17. [The ERC-2013-AdG 338936-BetaImage]
  18. Novo Nordisk Fonden [NNF12OC1016557] Funding Source: researchfish

向作者/读者索取更多资源

Insulin resistance and beta-cell failure are the major defects in type 2 diabetes mellitus. However, the molecular mechanisms linking these two defects remain unknown. Elevated levels of apolipoprotein CIII (apoCIII) are associated not only with insulin resistance but also with cardiovascular disorders and inflammation. We now demonstrate that local apoCIII production is connected to pancreatic islet insulin resistance and beta-cell failure. An increase in islet apoCIII causes promotion of a local inflammatory milieu, increased mitochondrial metabolism, deranged regulation of beta-cell cytoplasmic free Ca2+ concentration ([Ca2+](i)) and apoptosis. Decreasing apoCIII in vivo results in improved glucose tolerance, and pancreatic apoCIII knockout islets transplanted into diabetic mice, with high systemic levels of the apolipoprotein, demonstrate a normal [Ca2+](i) response pattern and no hallmarks of inflammation. Hence, under conditions of islet insulin resistance, locally produced apoCIII is an important diabetogenic factor involved in impairment of beta-cell function and may thus constitute a novel target for the treatment of type 2 diabetes mellitus.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据